Navigation Links
Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures
Date:5/22/2013

CAMBRIDGE, Mass., May 22, 2013 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced the appointment of Stephane Bancel as a Senior Partner. In this role, Mr. Bancel will provide strategic counsel and support to portfolio companies.

In addition to working closely with companies in the Flagship portfolio, Mr. Bancel also serves as President and Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs™ - founded company.  Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside the patient, within the patient's cells. This allows the in vivo expression of virtually any therapeutic protein for intracellular or systemic action. He is also Executive Chairman of the board for BG Medicine, Inc. (NASDAQ: BGMD), a Flagship portfolio company focused on the discovery, development and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs.

"Stephane brings with him a wealth of management experience and expertise in the development and commercialization of medical diagnostic tools and technologies as well as expertise in the pharmaceuticals industry," said Noubar Afeyan , Managing Partner and Chief Executive Officer of Flagship Ventures.  Under Mr. Bancel's leadership, Moderna has entered into one of the largest preclinical biotech-pharma deals in the industry's 35 year history with AstraZeneca. The recently announced partnership agreement involves up to 40 options to drug products and $420M in up front and technology milestone payments. Dr. Afeyan added, "having worked together with Stephane for over three years now at BG Medicine and Moderna, I look forward to seeing his commercial mindset and strategic insights applied more broadly to Flagship's investment strategy as well as to the growth and success of our portfolio companies." 

Mr. Bancel said "What attracted me to Flagship Ventures was the team's depth of experience and knowledge in the life sciences industry, as well as the firm's unique philosophy and approach to realizing entrepreneurial innovation." He continued, "I look forward to building on Flagship's growing reputation as one of the preeminent innovators in the life sciences ecosystem."

Prior to joining Flagship, Mr. Bancel served as Chief Executive Officer of bioMerieux (NYSE Euronext: BIM.PA), a world leader in the diagnostics industry. During his five years leading the company, he accelerated the sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. Under his leadership, the company's market capitalization nearly doubled despite the broader economic downturn.

Previously, Mr. Bancel was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He earned a Master of Engineering from Ecole Centrale Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. In 2009, Mr. Bancel was elected a Young Global Leader by the World Economic Forum. He was elected Best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.

About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio companies include:  Accuri Cytometers (acquired by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by Eli Lilly), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ: BGMD), Tetraphase (NASDAQ: TTPH), Receptos (NASDAQ: RCPT) and Morphotek (acquired by Eisai).  Additional notable portfolio companies include:  AeroDesigns, Affinnova, Agios, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna Therapeutics.  For more information, please visit www.flagshipventures.com.

 Contact:For Flagship Ventures: 

Rachel BrennerRuder Finn212.715.1623 flagship@ruderfinn.com 


'/>"/>
SOURCE Flagship Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
4. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
5. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... July 13, 2017  Centurion Medical Products, a leader in medical ... ® fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are ... help alleviate patient pain while preventing unneeded emergency department admission due ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
(Date:7/11/2017)... July 11, 2017  Sysmex America, Inc., a ... testing equipment as well as middleware information systems ... to make quality assurance easier and more risk ... well known for the innovation that it delivers ... elevates quality assurance processes to a new level ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... ... further expand its existing adherence automation lines. The ATP® Mini and InspectRx® ... technology of TCG’s standard products, but at a size and price point that ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, a ... major international travel insurance products online, under their own brand. The online marketplace ...
(Date:7/20/2017)... ... 2017 , ... A local summer theatre camp is celebrating ... support fine arts programs in Chester County’s Elementary Schools. In late June, students ... , More than 850 people attended the two performances, an increase from ...
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... Med Tech ... the Minnesota based Health IT business unit of Constellation Inc., a move that will ... established base of operations in St. Louis, the acquisition is expected to help ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th ... weight loss surgery patients who had received a body contouring procedure reported experiencing a ... clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that this ...
Breaking Medicine News(10 mins):